Lu Xudong, Qian Shuxia, Wang Yanping, Zhang Xiaoling, Jin Yuhua, Yu Bo
Xudong Lu, Department of Neurology, Jiaxing Second Hospital, Jiaxing, Zhejiang Province 314000, P.R. China.
Shuxia Qian, Department of Neurology, Jiaxing Second Hospital, Jiaxing, Zhejiang Province 314000, P.R. China.
Pak J Med Sci. 2024 Oct;40(9):1994-1999. doi: 10.12669/pjms.40.9.10100.
To explore the clinical efficacy of butylphthalide in treating patients with stroke attributed to intracranial artery stenosis (ICAS).
In this retrospective study, records of 163 patients with stroke attributed to ICAS admitted to Jiaxing Second Hospital from January 2021 to January 2023 were retrospectively analyzed. Patients were divided into two groups based on the treatment received: control group (patients received routine treatment, n=55) and observation group (patients treated with butylphthalide on a routine basis, n=58). Changes in levels of cerebrovascular reactivity (CVR), breath-holding index (BHI), pulsatility index (PI), and middle cerebral artery mean flow velocity (Vm) between the two groups before and after treatment were compared. In addition, cognitive function, neurological function, and living ability were compared between the two groups before and after treatment, as well as the overall clinical efficacy of the treatment.
The baseline data was comparable between the two groups (>0.05). After the treatment, CVR, BHI, and Vm indicators in the observation group were significantly higher than those in the control group, while the levels of PI indexes were significantly lower than those in the control group (<0.05). Montreal Cognitive Assessment (MoCA) and Barthel scale scores of the observation group were significantly higher compared to the control group, while the scores of National Institutes of Health Stroke Scale (NIHSS) were significantly lower (<0.05).
Butylphthalide in addition to routine treatment can effectively improve cerebrovascular reserve function, promote neurological and cognitive dysfunction recovery, and enhance daily living ability of patients with stroke caused by ICAS.
探讨丁苯酞治疗颅内动脉狭窄（ICAS）所致脑卒中患者的临床疗效。
本回顾性研究对2021年1月至2023年1月在嘉兴市第二医院收治的163例ICAS所致脑卒中患者的病历进行回顾性分析。根据接受的治疗将患者分为两组：对照组（接受常规治疗的患者，n = 55）和观察组（常规接受丁苯酞治疗的患者，n = 58）。比较两组治疗前后脑血管反应性（CVR）、屏气指数（BHI）、搏动指数（PI）和大脑中动脉平均血流速度（Vm）水平的变化。此外，比较两组治疗前后的认知功能、神经功能和生活能力，以及治疗的总体临床疗效。
两组基线数据具有可比性（>0.05）。治疗后，观察组的CVR、BHI和Vm指标显著高于对照组，而PI指标水平显著低于对照组（<0.05）。观察组的蒙特利尔认知评估（MoCA）和巴氏量表评分显著高于对照组，而美国国立卫生研究院卒中量表（NIHSS）评分显著低于对照组（<0.05）。
丁苯酞联合常规治疗可有效改善ICAS所致脑卒中患者的脑血管储备功能，促进神经和认知功能障碍恢复，提高患者日常生活能力。
